IBDEI184 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20451,1,3,0)
 ;;=3^Atypical Atrial Flutter
 ;;^UTILITY(U,$J,358.3,20451,1,4,0)
 ;;=4^I48.4
 ;;^UTILITY(U,$J,358.3,20451,2)
 ;;=^5007228
 ;;^UTILITY(U,$J,358.3,20452,0)
 ;;=Z71.89^^97^960^1
 ;;^UTILITY(U,$J,358.3,20452,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20452,1,3,0)
 ;;=3^Counseling,Other Specified
 ;;^UTILITY(U,$J,358.3,20452,1,4,0)
 ;;=4^Z71.89
 ;;^UTILITY(U,$J,358.3,20452,2)
 ;;=^5063253
 ;;^UTILITY(U,$J,358.3,20453,0)
 ;;=Z71.7^^97^960^2
 ;;^UTILITY(U,$J,358.3,20453,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20453,1,3,0)
 ;;=3^HIV Counseling
 ;;^UTILITY(U,$J,358.3,20453,1,4,0)
 ;;=4^Z71.7
 ;;^UTILITY(U,$J,358.3,20453,2)
 ;;=^5063251
 ;;^UTILITY(U,$J,358.3,20454,0)
 ;;=Z76.89^^97^960^3
 ;;^UTILITY(U,$J,358.3,20454,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20454,1,3,0)
 ;;=3^Persons Encountering Health Services for Oth Circumstances
 ;;^UTILITY(U,$J,358.3,20454,1,4,0)
 ;;=4^Z76.89
 ;;^UTILITY(U,$J,358.3,20454,2)
 ;;=^5063304
 ;;^UTILITY(U,$J,358.3,20455,0)
 ;;=E03.9^^97^961^25
 ;;^UTILITY(U,$J,358.3,20455,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20455,1,3,0)
 ;;=3^Hypothroidism,Unspec
 ;;^UTILITY(U,$J,358.3,20455,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,20455,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,20456,0)
 ;;=E11.9^^97^961^22
 ;;^UTILITY(U,$J,358.3,20456,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20456,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,20456,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,20456,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,20457,0)
 ;;=E10.9^^97^961^6
 ;;^UTILITY(U,$J,358.3,20457,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20457,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,20457,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,20457,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,20458,0)
 ;;=E11.65^^97^961^15
 ;;^UTILITY(U,$J,358.3,20458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20458,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,20458,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,20458,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,20459,0)
 ;;=E53.8^^97^961^30
 ;;^UTILITY(U,$J,358.3,20459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20459,1,3,0)
 ;;=3^Vitamin B Deficiency NEC
 ;;^UTILITY(U,$J,358.3,20459,1,4,0)
 ;;=4^E53.8
 ;;^UTILITY(U,$J,358.3,20459,2)
 ;;=^5002797
 ;;^UTILITY(U,$J,358.3,20460,0)
 ;;=E78.0^^97^961^29
 ;;^UTILITY(U,$J,358.3,20460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20460,1,3,0)
 ;;=3^Pure Hypercholesterolemia
 ;;^UTILITY(U,$J,358.3,20460,1,4,0)
 ;;=4^E78.0
 ;;^UTILITY(U,$J,358.3,20460,2)
 ;;=^5002966
 ;;^UTILITY(U,$J,358.3,20461,0)
 ;;=E78.5^^97^961^24
 ;;^UTILITY(U,$J,358.3,20461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20461,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,20461,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,20461,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,20462,0)
 ;;=E66.01^^97^961^27
 ;;^UTILITY(U,$J,358.3,20462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20462,1,3,0)
 ;;=3^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,20462,1,4,0)
 ;;=4^E66.01
 ;;^UTILITY(U,$J,358.3,20462,2)
 ;;=^5002826
 ;;^UTILITY(U,$J,358.3,20463,0)
 ;;=D64.9^^97^961^5
 ;;^UTILITY(U,$J,358.3,20463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20463,1,3,0)
 ;;=3^Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,20463,1,4,0)
 ;;=4^D64.9
 ;;^UTILITY(U,$J,358.3,20463,2)
 ;;=^5002351
 ;;^UTILITY(U,$J,358.3,20464,0)
 ;;=D68.318^^97^961^23
 ;;^UTILITY(U,$J,358.3,20464,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20464,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Intrns Circ Anticoag/Antibodies/Inhibitors
 ;;^UTILITY(U,$J,358.3,20464,1,4,0)
 ;;=4^D68.318
